Physician profile
Veronica A Constantine
NPI 1710955612
$3,085.26
in general payments reported to CMS, 2019-2025
16 companies · $348 in 2025
The $348 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.28 · 2020: $80.88 · 2021: $255 · 2022: $385 · 2023: $1,568 · 2024: $407 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,285 · Food and Beverage: $1,038.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,285.00 |
| Food and Beverage | $1,037.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,438.32 | 2022-2025 | Myday Contact Lens, Clariti Contact Lens |
| Johnson & Johnson Vision Care, INC. | $391.98 | 2019-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $290.09 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $241.90 | 2020-2025 | Precision7, Precision 1, Total30 |
| Tarsus Pharmaceuticals, INC. | $192.67 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $145.01 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $81.98 | 2021-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $70.81 | 2021-2022 | |
| Oyster Point Pharma, INC. | $45.56 | 2022 | |
| Abbvie INC. | $44.25 | 2022-2023 | Vuity, Lumigan, Alphagan P |
| Dompe US, INC. | $31.74 | 2024 | Oxervate |
| Allergan, INC. | $26.66 | 2022 | |
| Kala Pharmaceuticals, INC. | $24.53 | 2021 | |
| Harrow Eye, LLC | $23.77 | 2024 | Vevye |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $16.59 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Constantine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.